Loading.
Preparing your Shotlee experience
Authenticating
Loading health data
Syncing preferences
Pharmaceuticals
Cipla Introduces Tirzepatide Drug Yurpeak for Diabetes and Obesity Treatment in India
S
Shotlee
Health & Wellness Team
3 min read
Preparing your Shotlee experience
Cipla has released Yurpeak (tirzepatide), a weekly injectable medication designed for adults managing obesity and type 2 diabetes. As the second tirzepatide brand from Lilly available in India, Yurpeak will be accessible through prescription in a user-friendly KwikPen.
Cipla has launched Yurpeak (tirzepatide), a once-weekly injectable medication intended for adult patients dealing with obesity and type 2 diabetes. As the second brand of Lilly's tirzepatide to be offered in India, Yurpeak will be available with a prescription in a multi-dose KwikPen.
Cipla Limited announced the introduction of Yurpeak (tirzepatide), a once-weekly injectable treatment option for managing both obesity and type 2 diabetes mellitus (T2DM). These conditions represent two of the most significant health challenges currently facing the country.
Cipla possesses the exclusive rights to distribute and promote Yurpeak, which is the second brand of Lilly's tirzepatide in India, following its approval by the Drugs Controller General of India (DCGI). Tirzepatide stands out as the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is indicated as an addition to diet and exercise for treating Type 2 diabetes and aiding in chronic weight management for obese adults (BMI >= 30) or overweight individuals (BMI >= 27) who also have at least one weight-related comorbidity.
Yurpeak will be offered via prescription in the KwikPen format, with six available strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. This variety of dosages allows for precise, convenient, and user-friendly administration for patients. Health tracking apps like Shotlee can help monitor treatment progress and adherence.
According to Achin Gupta, Global Chief Operating Officer at Cipla Limited, the launch of Yurpeak signifies a major advancement in addressing obesity and type 2 diabetes mellitus, two chronic conditions that significantly burden India. Cipla is leveraging its established expertise and dedication to scientific advancement in chronic diseases and respiratory care to enter this therapeutic area. The company aims to improve access to advanced, globally recognized treatments through collaborations with companies like Lilly, combining innovation, purpose, and scale to ensure patients receive cutting-edge care wherever they are.
The availability of Yurpeak in India is expected to broaden access to tirzepatide, enabling more patients to experience the benefits of this innovative treatment. Cipla's main goal is to ensure Yurpeak's availability throughout India, including areas beyond major metropolitan centers. This will be achieved by utilizing its robust distribution network and in-depth understanding of the market to increase nationwide reach and accessibility.
Lilly will be responsible for manufacturing and supplying Yurpeak to Cipla, and its price will be consistent with that of Mounjaro.
To support the introduction of Yurpeak, Cipla will provide comprehensive patient education and support programs. These will include instructions on dosing, self-administration, and the safe and informed use of the medication. These initiatives are intended to help patients confidently manage their treatment under the guidance of their healthcare providers. This approach reflects Cipla's ongoing commitment to providing evidence-based information and responsible care, empowering individuals to proactively manage their health and adopt sustainable wellness practices.
⚠️ Disclaimer: This article is for informational purposes only. Consult your healthcare provider before starting any medication or supplement.
Original content from Asianet News Network Pvt Ltd
View Original Article
The global Peptide Therapeutics Market is experiencing substantial growth, projected to reach USD 82.19 billion by 2032. This expansion is fueled by the increasing need for specialized medications, particularly in oncology and metabolic diseases. The U.S. market is expected to reach USD 35.71 billion by 2032.
Dr. Reddy's Laboratories (DRL) is banking on semaglutide for future revenue, but faces challenges in securing timely approvals. The company aims to launch the drug domestically after patent expiration, while also navigating international regulatory hurdles.
An Indian court has granted Dr. Reddy's Laboratories Ltd permission to manufacture and export generic versions of Novo Nordisk's diabetes and obesity medications. This decision comes before the global patent expirations in 2026. The ruling allows export to countries without patent protection.
Monitor GLP-1 medications, peptide therapy, weight loss, and wellness metrics with our comprehensive health tracking app. Join thousands of users taking control of their health!
Start Tracking Free Forever! ✨